製品番号: HY-10982

Amonafide

(別名: AS1413)

5 Cited Publications

カスタマーレビュー

Based on 5 publication(s) in Google Scholar

Amonafide is a topoisomerase II inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.92%
CAS 番号: 69408-81-7
分子式: C₁₆H₁₇N₃O₂
分子量:283.33

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Amonafide 構造式

CAS 番号: 69408-81-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
化学情報
Publications (5)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Amonafide is a topoisomerase II inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.

IC₅₀ & Target^[1]

Topoisomerase II

Topoisomerase アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A 172	GI₅₀	>25 μM Compound: AM	Growth inhibition of human A172 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human A172 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
A 172	GI₅₀	>25 μM Compound: AM	Growth inhibition of human A172 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human A172 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
A 172	IC₅₀	23.81 μM Compound: Amonafide	Cytotoxicity against human A 172 cells assessed as cell viability measured after 96 hrs by XTT assay Cytotoxicity against human A 172 cells assessed as cell viability measured after 96 hrs by XTT assay	[PMID: 34507011]
A2780	IC₅₀	11.66 μM Compound: Amonafide	Antiproliferative activity against human A2780 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human A2780 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
A-375	IC₅₀	14.7 μM Compound: B2	Cytotoxicity against human A375 cells in hypoxic condition after 24 hrs by MTT assay Cytotoxicity against human A375 cells in hypoxic condition after 24 hrs by MTT assay	[PMID: 17331719]
A-375	IC₅₀	7.51 μM Compound: Amonafide	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 19643513]
A549	IC₅₀	1.1 μM Compound: Am	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 23353750]
A549	IC₅₀	1.1 μM Compound: B2	Cytotoxicity against human A549 cells by sulforhodamine B dye staining method Cytotoxicity against human A549 cells by sulforhodamine B dye staining method	[PMID: 17331719]
A549	IC₅₀	1.59 μM Compound: Amonafide	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	10.1039/C5MD00543D
A549	IC₅₀	1100 nM Compound: 1	Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.	[PMID: 10956214]
A549	IC₅₀	1100 nM Compound: Amonafide	Cytotoxic concentration against human A549 lung cancer cell line determined by sulforhodamine B dye-staining method Cytotoxic concentration against human A549 lung cancer cell line determined by sulforhodamine B dye-staining method	[PMID: 15876532]
A549	IC₅₀	1100 nM Compound: amonafide	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B dye assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B dye assay	[PMID: 17707644]
A549	IC₅₀	1100 nM Compound: 1, amonafide	Activity against A549 cancer cell line. Activity against A549 cancer cell line.	[PMID: 8960558]
A549	IC₅₀	12.37 μM Compound: Amon	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
A549	IC₅₀	13 μM Compound: amonafide	Growth inhibition of human A549 cells by SRB assay Growth inhibition of human A549 cells by SRB assay	[PMID: 17532640]
A549	IC₅₀	13 μM Compound: Amonafide	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 19643513]
A549	IC₅₀	13 μM Compound: Amonafide	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24370011]
A549	IC₅₀	2 μM Compound: Amonafide	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 29342415]
A549	IC₅₀	23.46 μM Compound: Amonafide	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
A549	IC₅₀	3.2 μM Compound: Am	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 23770449]
A549	IC₅₀	3.8 μM Compound: 1, amonafide	Antiproliferative activity against A549 cells after 72 hrs by MTT assay Antiproliferative activity against A549 cells after 72 hrs by MTT assay	[PMID: 17658777]
A549	IC₅₀	4.3 μM Compound: ANF	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth Antiproliferative activity against human A549 cells assessed as inhibition of cell growth	[PMID: 37974948]
A549	IC₅₀	7.76 μM Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30774856]
A549	IC₅₀	7.94 μM Compound: Amonafide	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 33109400]
A549	IC₅₀	8.1 μM Compound: Amonafide	Growth inhibition of human A549 cells measured after 72 hrs by SRB assay Growth inhibition of human A549 cells measured after 72 hrs by SRB assay	[PMID: 22000922]
A549	IC₅₀	9.56 μM Compound: Amonafide	Cytotoxicity against cisplatin-resistant human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against cisplatin-resistant human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
B16-F10	IC₅₀	6.7 μM Compound: Amonafide	Cytotoxicity against mouse B16F10 cells measured after 2 days by MTS assay Cytotoxicity against mouse B16F10 cells measured after 2 days by MTS assay	[PMID: 27939348]
BT-474	IC₅₀	37.8 μM Compound: Amonafide	Cytotoxicity against human BT474 cells after 3 days by MTT assay Cytotoxicity against human BT474 cells after 3 days by MTT assay	[PMID: 24835201]
Cancer cell lines	IC₅₀	2031 nM Compound: 2	Tested against UACC375 human melanoma cancer cells by sulforhodamine B (SRB) assay Tested against UACC375 human melanoma cancer cells by sulforhodamine B (SRB) assay	[PMID: 8459403]
Ca-Ski	IC₅₀	9.96 μM Compound: Amonafide	Cytotoxicity against human CaSki cells after 3 days by MTT assay Cytotoxicity against human CaSki cells after 3 days by MTT assay	[PMID: 24835201]
CNE-2	IC₅₀	8.65 μM Compound: Amonafide	Antiproliferative activity against human CNE-2 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human CNE-2 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
CT26	IC₅₀	11.69 μM Compound: Amonafide	Growth inhibition of mouse CT26 cells after 24 hrs by MTT assay Growth inhibition of mouse CT26 cells after 24 hrs by MTT assay	[PMID: 29990424]
GES1	IC₅₀	21.6 μM Compound: Am	Cytotoxicity against human GES-1 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human GES-1 cells after 72 hrs by sulforhodamine B assay	[PMID: 23770449]
HCT-116	IC₅₀	15.3 μM Compound: Amonafide	Growth inhibition of human HCT116 cells measured after 72 hrs by SRB assay Growth inhibition of human HCT116 cells measured after 72 hrs by SRB assay	[PMID: 22000922]
HCT-116	IC₅₀	2.7 μM Compound: Amonafide	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by XTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by XTT assay	[PMID: 30312931]
HCT-116	IC₅₀	25.73 μM Compound: Amon	Antiproliferative activity against human HCT-116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
HCT-116	IC₅₀	32 μM Compound: amonafide	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22428910]
HCT-116	IC₅₀	4.55 μM Compound: 3, ST	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 22138307]
HCT-116	IC₅₀	6.46 μM Compound: Amonafide	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30151093]
HCT-116	IC₅₀	6.86 μM Compound: Amonafide	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29133040]
HCT-116	IC₅₀	7.18 μM Compound: Amonafide	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 29990424]
HCT-116	IC₅₀	8.55 μM Compound: Amonafide	Growth inhibition of human HCT116 cells after 24 hrs by MTT assay Growth inhibition of human HCT116 cells after 24 hrs by MTT assay	[PMID: 29990424]
HCT-15	IC₅₀	5.2 μM Compound: 1, amonafide	Antiproliferative activity against HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against HCT15 cells after 72 hrs by MTT assay	[PMID: 17658777]
HCT-8	IC₅₀	9.26 μM Compound: Amonafide	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 19643513]
HEL	IC₅₀	3.4 μM Compound: AM	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 24054489]
HEL	IC₅₀	4 μM Compound: Amonafide	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 28233678]
HeLa	IC₅₀	0.68 μM Compound: amonafide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19070496]
HeLa	IC₅₀	1.4 μM Compound: amonafide	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 17532640]
HeLa	IC₅₀	1.4 μM Compound: Amonafide	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19643513]
HeLa	IC₅₀	1.73 μM Compound: Amonafide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21345546]
HeLa	IC₅₀	10.67 μM Compound: Amonofide	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20170164]
HeLa	IC₅₀	2.73 μM Compound: Amonafid	In vitro cytotoxicity against human cervical carcinoma (HeLa) cell line In vitro cytotoxicity against human cervical carcinoma (HeLa) cell line	[PMID: 14998328]
HeLa	IC₅₀	2.73 μM Compound: Amonafide	In vitro concentration required to reduce cell number to 50% in human cervical carcinoma (HeLa) culture In vitro concentration required to reduce cell number to 50% in human cervical carcinoma (HeLa) culture	[PMID: 12477366]
HeLa	IC₅₀	2.73 μM Compound: amonafide	Growth inhibitory concentration against human cervical carcinoma (HeLa) cell line Growth inhibitory concentration against human cervical carcinoma (HeLa) cell line	[PMID: 15084122]
HeLa	IC₅₀	3.41 μM Compound: Amonafide	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 29342415]
HeLa	IC₅₀	4.36 μM Compound: Amonafide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	10.1039/C5MD00543D
HeLa	IC₅₀	6.02 μM Compound: amonafide	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21208805]
HeLa	IC₅₀	6.71 μM Compound: Amonafide	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24370011]
HeLa	IC₅₀	9.52 μM Compound: AM	Cytotoxicity against human HeLa cells incubated for 24 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells incubated for 24 hrs by sulforhodamine B assay	[PMID: 26211460]
HepG2	IC₅₀	1.41 μM Compound: 3, ST	Cytotoxicity against human HepG2 after 72 hrs by MTT assay Cytotoxicity against human HepG2 after 72 hrs by MTT assay	[PMID: 22138307]
HepG2	IC₅₀	1.71 μM Compound: Amonafide	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 24835201]
HepG2	IC₅₀	10.11 μM Compound: Amonafide	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28177238]
HepG2	IC₅₀	11.67 μM Compound: Amonafide	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29133040]
HepG2	IC₅₀	11.67 μM Compound: Amonafide	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	[PMID: 29990424]
HepG2	IC₅₀	36 μM Compound: amonafide	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22428910]
HepG2	IC₅₀	6.45 μM Compound: amonafide	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21208805]
HepG2	IC₅₀	7.94 μM Compound: Amonafide	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 37972528]
HepG2	IC₅₀	9.38 μM Compound: Amonafide	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
HepG2	IC₅₀	9.38 μM Compound: Amonafide	Cytotoxicity against human HepG2 cells assessed as inhibitory of cell growth measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibitory of cell growth measured after 24 hrs by MTT assay	[PMID: 33965862]
HepG2	IC₅₀	9.45 μM Compound: Amonafide	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30151093]
HK-2	IC₅₀	27.15 μM Compound: Amon	Cytotoxicity against HK-2 cells incubated for 48 hrs by MTT assay Cytotoxicity against HK-2 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
HL-60	IC₅₀	0.9 μM Compound: Am	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 23770449]
HL-60	IC₅₀	1.63 μM Compound: amonafide	Growth inhibition of human HL60 cells by MTT assay Growth inhibition of human HL60 cells by MTT assay	[PMID: 17532640]
HL-60	IC₅₀	17.96 μM Compound: Amonafide	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19643513]
HL-60	IC₅₀	17.96 μM Compound: Amonofide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20170164]
HL-60	IC₅₀	3.4 μM Compound: Amonafide	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 28233678]
Hs 683	IC₅₀	3.9 μM Compound: 1, amonafide	Antiproliferative activity against Hs683 cells after 72 hrs by MTT assay Antiproliferative activity against Hs683 cells after 72 hrs by MTT assay	[PMID: 17658777]
HT-29	IC₅₀	3 μM Compound: Amonafide	In vitro cytotoxicity against HT-29 (human colon adenocarcinoma) cell line. In vitro cytotoxicity against HT-29 (human colon adenocarcinoma) cell line.	[PMID: 9046334]
HT-29	IC₅₀	4.67 μM Compound: Amonafid	In vitro cytotoxicity against human colon carcinoma (HT-29) cell line In vitro cytotoxicity against human colon carcinoma (HT-29) cell line	[PMID: 14998328]
HT-29	IC₅₀	4.67 μM Compound: Amonafide	In vitro concentration required to reduce cell number to 50% in human colon carcinoma (HT-29) culture In vitro concentration required to reduce cell number to 50% in human colon carcinoma (HT-29) culture	[PMID: 12477366]
HT-29	IC₅₀	4.67 μM Compound: amonafide	Growth inhibitory concentration against human colon adenocarcinoma cell line (HT-29) Growth inhibitory concentration against human colon adenocarcinoma cell line (HT-29)	[PMID: 15084122]
HT-29	IC₅₀	5.46 μM Compound: 1	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30774856]
Huh-7	IC₅₀	8.52 μM Compound: Amonafide	Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
Huh-7	IC₅₀	8.52 μM Compound: Amonafide	Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay	[PMID: 33965862]
HUVEC	IC₅₀	21.91 μM Compound: Amon	Cytotoxicity against HUVEC cells incubated for 48 hrs by MTT assay Cytotoxicity against HUVEC cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
K562	IC₅₀	>50 μM Compound: Amonafide	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 22436386]
K562	IC₅₀	10.1 μM Compound: Amonafide	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 29133040]
K562	IC₅₀	20.11 μM Compound: Amonafide	Growth inhibition of human K562 cells after 48 hrs by MTT assay Growth inhibition of human K562 cells after 48 hrs by MTT assay	[PMID: 29990424]
K562	IC₅₀	31.7 μM Compound: amonafide	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 22428910]
L02	IC₅₀	11.56 μM Compound: Amonafide	Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay	[PMID: 33965862]
L02	IC₅₀	13.8 μM Compound: Am	Cytotoxicity against human LO2 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human LO2 cells after 72 hrs by sulforhodamine B assay	[PMID: 23770449]
L02	IC₅₀	5 μM Compound: Am	Cytotoxicity against human LO2 cells by SRB assay Cytotoxicity against human LO2 cells by SRB assay	[PMID: 23353750]
L1210	IC₅₀	1612 nM Compound: Amonafide	An average for IC50 values in the two solid tumor cell lines and sensitive L1210 leukemia cell line. An average for IC50 values in the two solid tumor cell lines and sensitive L1210 leukemia cell line.	[PMID: 8648600]
L1210	IC₅₀	625 nM Compound: 1	Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay. Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay.	[PMID: 10956214]
L1210	IC₅₀	625 nM Compound: 1	Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay. Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay.	[PMID: 10956214]
L1210	IC₅₀	625 nM Compound: 1	Antitumor activity against murine L1210 resistant cell line by using MTT assay Antitumor activity against murine L1210 resistant cell line by using MTT assay	[PMID: 7699715]
L1210	IC₅₀	625 nM Compound: 1	Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay	[PMID: 7699715]
L1210	IC₅₀	625 nM Compound: 2	Tested against L1210 resistant murine leukemia cells by MTT tetrazolium dye assay Tested against L1210 resistant murine leukemia cells by MTT tetrazolium dye assay	[PMID: 8459403]
L1210	IC₅₀	625 nM Compound: 2	Tested against L1210 sensitive murine leukemia cells by MTT tetrazolium dye assay Tested against L1210 sensitive murine leukemia cells by MTT tetrazolium dye assay	[PMID: 8459403]
L1210	IC₅₀	625 nM Compound: 1, amonafide	Antitumor activity against murine leukemia L1210 cell line. Antitumor activity against murine leukemia L1210 cell line.	[PMID: 8960558]
L1210	IC₅₀	625 nM Compound: 1, amonafide	Antitumor activity against sensitive L1210 murine leukemia cell lines. Antitumor activity against sensitive L1210 murine leukemia cell lines.	[PMID: 8960558]
L1210	IC₅₀	625 nM Compound: Amonafide	Inhibitory activity against resistant murine leukemia L1210 cell lines. Inhibitory activity against resistant murine leukemia L1210 cell lines.	[PMID: 8648600]
L1210	IC₅₀	625 nM Compound: Amonafide	Inhibitory activity against sensitive L1210 cell lines Inhibitory activity against sensitive L1210 cell lines	[PMID: 8648600]
LoVo	IC₅₀	2.7 μM Compound: 1, amonafide	Antiproliferative activity against LoVo cells after 72 hrs by MTT assay Antiproliferative activity against LoVo cells after 72 hrs by MTT assay	[PMID: 17658777]
LS174T	IC₅₀	20.28 μM Compound: Amonofide	Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay	[PMID: 20170164]
MCF7	IC₅₀	1.68 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21345546]
MCF7	IC₅₀	1.68 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24370011]
MCF7	IC₅₀	10.93 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
MCF7	IC₅₀	11.88 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19643513]
MCF7	IC₅₀	11.88 μM Compound: Amonofide	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20170164]
MCF7	IC₅₀	1100 nM Compound: 1	Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	1100 nM Compound: 1, amonafide	Antitumor activity against human mammary carcinoma sensitive MXF7 breast cell line. Antitumor activity against human mammary carcinoma sensitive MXF7 breast cell line.	[PMID: 8960558]
MCF7	IC₅₀	12.92 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30151093]
MCF7	IC₅₀	1200 nM Compound: 1	Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	1200 nM Compound: 1, amonafide	Antitumor activity against human mammary carcinoma mitoxantrone-resistant MXF7 breast cell line. Antitumor activity against human mammary carcinoma mitoxantrone-resistant MXF7 breast cell line.	[PMID: 8960558]
MCF7	IC₅₀	1800 nM Compound: 1	Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	1800 nM Compound: 1, amonafide	Antitumor activity against human mammary carcinoma doxorubicin-resistant MXF7 breast cell line. Antitumor activity against human mammary carcinoma doxorubicin-resistant MXF7 breast cell line.	[PMID: 8960558]
MCF7	IC₅₀	4.05 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30774856]
MCF7	IC₅₀	5.8 μM Compound: 1, amonafide	Antiproliferative activity against MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against MCF7 cells after 72 hrs by MTT assay	[PMID: 17658777]
MCF7	IC₅₀	6.79 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 29342415]
MCF7	IC₅₀	8.02 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	10.1039/C5MD00543D
MDA-MB-231	GI₅₀	>25 μM Compound: AM	Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
MDA-MB-231	GI₅₀	>25 μM Compound: AM	Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
MDA-MB-231	IC₅₀	15.23 μM Compound: Amonafide	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
MDA-MB-231	IC₅₀	21.08 μM Compound: Amon	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
MDA-MB-231	IC₅₀	4.4 μM Compound: Am	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 23770449]
MDA-MB-231	IC₅₀	42 μM Compound: amonafide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 22428910]
MDA-MB-231	IC₅₀	6.62 μM Compound: Amonafide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 30151093]
MDA-MB-238	IC₅₀	24.25 μM Compound: Amonafide	Cytotoxicity against human MDA-MB-238 cells assessed as cell viability measured after 96 hrs by XTT assay Cytotoxicity against human MDA-MB-238 cells assessed as cell viability measured after 96 hrs by XTT assay	[PMID: 34507011]
MGC-803	IC₅₀	3.23 μM Compound: Amonafide	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 29342415]
MGC-803	IC₅₀	5.25 μM Compound: Amonafide	Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
MGC-803	IC₅₀	9.06 μM Compound: Amonafide	Antiproliferative activity against human MGC-803 cells by MTT assay Antiproliferative activity against human MGC-803 cells by MTT assay	[PMID: 33109400]
MGC-803	IC₅₀	9.06 μM Compound: Amon	Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
MGC-803	IC₅₀	9.06 μM Compound: Amonafide	Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay	[PMID: 37972528]
MKN-45	IC₅₀	>50 μM Compound: Amonofide	Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 20170164]
NB-4	IC₅₀	5.7 μM Compound: ANF	Antiproliferative activity against human NB4 cells assessed as inhibition of cell growth Antiproliferative activity against human NB4 cells assessed as inhibition of cell growth	[PMID: 37974948]
NCI-H1299	GI₅₀	>25 μM Compound: AM	Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
NCI-H1299	GI₅₀	>25 μM Compound: AM	Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
NCI-H1299	IC₅₀	8.84 μM Compound: Amonafide	Cytotoxicity against human NCI-H1299 cells assessed as cell viability measured after 96 hrs by XTT assay Cytotoxicity against human NCI-H1299 cells assessed as cell viability measured after 96 hrs by XTT assay	[PMID: 34507011]
NCI-H460	IC₅₀	7.8 μM Compound: amonafide	Antiproliferative activity against human NCI-H460 cells after 72 hrs Antiproliferative activity against human NCI-H460 cells after 72 hrs	[PMID: 18061459]
OVCAR-3	IC₅₀	2180 nM Compound: 1	Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay.	[PMID: 10956214]
OVCAR-3	IC₅₀	2180 nM Compound: 1	Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay	[PMID: 7699715]
OVCAR-3	IC₅₀	2180 nM Compound: 2	Tested against OVCAR-3 human ovarian cancer cells by sulforhodamine B (SRB) assay Tested against OVCAR-3 human ovarian cancer cells by sulforhodamine B (SRB) assay	[PMID: 8459403]
OVCAR-3	IC₅₀	2180 nM Compound: 1, amonafide	Compound was tested for antitumor activity against 33 Human ovarian (OVCAR-3) cell lines. Compound was tested for antitumor activity against 33 Human ovarian (OVCAR-3) cell lines.	[PMID: 8960558]
OVCAR-3	IC₅₀	2180 nM Compound: Amonafide	Inhibitory activity against OVCAR-3 cell line Inhibitory activity against OVCAR-3 cell line	[PMID: 8648600]
P388	IC₅₀	0.2 μM Compound: Am	Cytotoxicity against mouse P388 cells by tetrazolium-formazan assay Cytotoxicity against mouse P388 cells by tetrazolium-formazan assay	[PMID: 23353750]
P388	IC₅₀	0.2 μM Compound: B2	Cytotoxicity against mouse P388 cells by tetrazolium-formazan method Cytotoxicity against mouse P388 cells by tetrazolium-formazan method	[PMID: 17331719]
P388	IC₅₀	200 nM Compound: Amonafide	Cytotoxic concentration against murine P388 leukemia cell line growth determined by microculture tetrazolium-formazan method Cytotoxic concentration against murine P388 leukemia cell line growth determined by microculture tetrazolium-formazan method	[PMID: 15876532]
P388	IC₅₀	200 nM Compound: amonafide	Cytotoxicity against mouse P388 cells after 48 hrs by tetrazolium-formazan method Cytotoxicity against mouse P388 cells after 48 hrs by tetrazolium-formazan method	[PMID: 17707644]
P388	IC₅₀	4.56 μM Compound: amonafide	Growth inhibition of mouse P388 cells by MTT assay Growth inhibition of mouse P388 cells by MTT assay	[PMID: 17532640]
P388	IC₅₀	4.56 μM Compound: Amonafide	Cytotoxicity against mouse P388 cells by MTT assay Cytotoxicity against mouse P388 cells by MTT assay	[PMID: 19643513]
P388D1	IC₅₀	0.68 μM Compound: amonafide	Antiproliferative activity against mouse P388D1 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388D1 cells after 48 hrs by MTT assay	[PMID: 21208805]
P388D1	IC₅₀	6.02 μM Compound: amonafide	Cytotoxicity against mouse P388D1 cells after 48 hrs by MTT assay Cytotoxicity against mouse P388D1 cells after 48 hrs by MTT assay	[PMID: 19070496]
PANC-1	IC₅₀	2.7 μM Compound: Amonafide	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 24 hrs by XTT assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 24 hrs by XTT assay	[PMID: 30312931]
PC-3	GI₅₀	>25 μM Compound: AM	Growth inhibition of human PC3 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human PC3 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
PC-3	GI₅₀	>25 μM Compound: AM	Growth inhibition of human PC3 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human PC3 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
PC-3	IC₅₀	6.38 μM Compound: Amonafid	In vitro cytotoxicity against human prostate carcinoma (PC-3) cell line In vitro cytotoxicity against human prostate carcinoma (PC-3) cell line	[PMID: 14998328]
PC-3	IC₅₀	6.38 μM Compound: Amonafide	In vitro concentration required to reduce cell number to 50% in human postrate carcinoma (PC-3) culture In vitro concentration required to reduce cell number to 50% in human postrate carcinoma (PC-3) culture	[PMID: 12477366]
PC-3	IC₅₀	6.38 μM Compound: amonafide	Growth inhibitory concentration against human prostate carcinoma (PC-3) cell line Growth inhibitory concentration against human prostate carcinoma (PC-3) cell line	[PMID: 15084122]
PC-3	IC₅₀	8.05 μM Compound: 3, ST	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 22138307]
SGC-7901	IC₅₀	5.32 μM Compound: Amonafide	Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay	10.1039/C5MD00543D
SK-BR-3	IC₅₀	7.4 μM Compound: AM	Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay	[PMID: 24054489]
SK-BR-3	IC₅₀	7.4 μM Compound: Amonafide	Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay	[PMID: 28233678]
SK-OV-3	IC₅₀	6.31 μM Compound: Amonafide	Antiproliferative activity against human SK-OV-3 cells by MTT assay Antiproliferative activity against human SK-OV-3 cells by MTT assay	[PMID: 33109400]
SK-OV-3	IC₅₀	6.31 μM Compound: Amonafide	Antiproliferative activity against human SK-OV-3 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells incubated for 48 hrs by MTT assay	[PMID: 37972528]
SK-OV-3	IC₅₀	8.83 μM Compound: 3, ST	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 22138307]
SMMC-7721	IC₅₀	10.32 μM Compound: Amonafide	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 29133040]
SMMC-7721	IC₅₀	10.32 μM Compound: Amonafide	Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 29990424]
SMMC-7721	IC₅₀	4.15 μM Compound: amonafide	Growth inhibition of human SMMC7721 cells by MTT assay Growth inhibition of human SMMC7721 cells by MTT assay	[PMID: 17532640]
SMMC-7721	IC₅₀	4.27 μM Compound: Amonafide	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 21345546]
SMMC-7721	IC₅₀	6.93 μM Compound: Amonafide	Antiproliferative activity against human SMMC-7721 cells by MTT assay Antiproliferative activity against human SMMC-7721 cells by MTT assay	[PMID: 33109400]
SMMC-7721	IC₅₀	9.37 μM Compound: Amonafide	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 30151093]
SMMC-7721	IC₅₀	9.95 μM Compound: Amonafide	Cytotoxicity against human SMMC7721 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28177238]
SW-620	IC₅₀	0.32 μM Compound: Amonafide	Cytotoxicity against human SW620 cells after 3 days by MTT assay Cytotoxicity against human SW620 cells after 3 days by MTT assay	[PMID: 24835201]
T-24	IC₅₀	5.01 μM Compound: Amonafide	Antiproliferative activity against human T-24 cells by MTT assay Antiproliferative activity against human T-24 cells by MTT assay	[PMID: 33109400]
T-24	IC₅₀	5.01 μM Compound: Amonafide	Antiproliferative activity against human T24 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human T24 cells incubated for 48 hrs by MTT assay	[PMID: 37972528]
T-24	IC₅₀	7.23 μM Compound: Amonafide	Antiproliferative activity against human T24 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human T24 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
T-24	IC₅₀	7.94 μM Compound: Amon	Antiproliferative activity against human T24 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human T24 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
U-251	IC₅₀	>50 μM Compound: Amon	Antiproliferative activity against human U-251 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human U-251 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
U-373MG ATCC	IC₅₀	3.5 μM Compound: 1, amonafide	Antiproliferative activity against U373MG cells after 72 hrs by MTT assay Antiproliferative activity against U373MG cells after 72 hrs by MTT assay	[PMID: 17658777]
U-87MG ATCC	IC₅₀	2.8 μM Compound: 3, ST	Cytotoxicity against human U87MG cells after 72 hrs by MTT assay Cytotoxicity against human U87MG cells after 72 hrs by MTT assay	[PMID: 22138307]
UACC-375	IC₅₀	2031 nM Compound: 1	Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay.	[PMID: 10956214]
UACC-375	IC₅₀	2031 nM Compound: 1	Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay	[PMID: 7699715]
UACC-375	IC₅₀	2031 nM Compound: 1, amonafide	Antitumor activity against human melanoma UACC375 cell line. Antitumor activity against human melanoma UACC375 cell line.	[PMID: 8960558]
UACC-375	IC₅₀	2031 nM Compound: Amonafide	Inhibitory activity against AUC375 cell line Inhibitory activity against AUC375 cell line	[PMID: 8648600]
V79	IC₅₀	70.3 μM Compound: B2	Cytotoxicity against V79 cells in hypoxic condition after 24 hrs by MTT assay Cytotoxicity against V79 cells in hypoxic condition after 24 hrs by MTT assay	[PMID: 17331719]
WiDr	IC₅₀	1100 nM Compound: 1	Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein). Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	[PMID: 10956214]
WiDr	IC₅₀	1100 nM Compound: 1, amonafide	Activity against human colon carcinoma sensitive WiDr cell line. Activity against human colon carcinoma sensitive WiDr cell line.	[PMID: 8960558]
WiDr	IC₅₀	2200 nM Compound: 1	Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein). Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	[PMID: 10956214]
WiDr	IC₅₀	2200 nM Compound: 1, amonafide	Activity against human colon carcinoma multi drug resistant (MDR)-WiDr cell line. Activity against human colon carcinoma multi drug resistant (MDR)-WiDr cell line.	[PMID: 8960558]
WM 266-4	GI₅₀	>25 μM Compound: AM	Growth inhibition of human WM266.4 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human WM266.4 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
WM 266-4	GI₅₀	>25 μM Compound: AM	Growth inhibition of human WM266.4 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human WM266.4 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
WM 266-4	IC₅₀	6.92 μM Compound: Amonafide	Cytotoxicity against human WM 266-4 cells assessed as cell viability measured after 96 hrs by XTT assay Cytotoxicity against human WM 266-4 cells assessed as cell viability measured after 96 hrs by XTT assay	[PMID: 34507011]

体外実験

Amonafide is a topoisomerase II inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA^[1]. Amonafide produces protein-associated DNA cleavage, single-strand breaks (SSB) and DPC and DNA double-strand cleavage. Amonafide (Nafidimide, 400 nM-2.4 μM) reduces the colony-forming ability of the leukemic cell lines in a dose-dependent manner^[2]. Amonafide (0.05-0.4 μg/mL) reduces several tumor growth. However, Amonafide is active against only 12% of tumors compared with standard agents (5-fluorouracil, mitomycin C, cisplatin, and etoposide), which are active against more than 40% of tumors in the human bone marrow inhibitory range^[3]. Amonafide inhibits the growth of HT-29, HeLa, and PC-3 cell lines, with IC₅₀s of 4.67, 2.73, and 6.38 μM^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 69408-81-7
性状 Solid
分子量 283.33
分子式 C₁₆H₁₇N₃O₂
Color Light yellow to yellow
SMILES

O=C1N(C(C2=CC(N)=CC3=CC=CC1=C23)=O)CCN(C)C
別名

AS1413
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All

Sort by:

Journal Impact Factor

ACS Appl Mater Interfaces

Drastic Modulation of Molecular Packing and Intrinsic Dissolution Rates by Meniscus-Guided Coating of Extremely Confined Pharmaceutical Thin Films. [Abstract]

2021 Dec 1;13(47):56519-56529. PMID: 34783517
Anal Chem

Metal-Enhanced Aggregation-Induced Emission Strategy for the HIV-I RNA-Binding Ligand Assay. [Abstract]

2022 Mar 22;94(11):4695-4702. PMID: 35258935
J Am Heart Assoc

Amonafide Targeting NTSR1-PI3K/AKT/mTOR Signaling Attenuates Vascular Remodeling in Pulmonary Arterial Hypertension. [Abstract]

2026 May 19;15(10):e045580. PMID: 42132175
PLoS One

Drug repositioning for pan-cancers of the digestive system: Identification of amonafide and BX795 as potential therapeutics via integrative Omics analysis. [Abstract]

2025 Jun 16;20(6):e0325700. PMID: 40522954
Cancer Manag Res

UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway. [Abstract]

2019 Mar 22:11:2339-2348. PMID: 30962721

溶剤 & 溶解度

体外:

DMSO : 41.67 mg/mL (147.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5295 mL

17.6473 mL

35.2945 mL

5 mM

0.7059 mL

3.5295 mL

7.0589 mL

10 mM

0.3529 mL

1.7647 mL

3.5295 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (7.34 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[2]

In experiments measuring survival following 1 h drug treatments, 2 × 10⁶cells are resuspended in 2 mL warm (37°C) HBSS with 5% PCS; the appropriate drug (Amonafide) level is attained with the addition of less than 50 μL. Cells are incubated for 60 min at 37°C after which 10 mL ice cold PBS is added. The cells are then centrifuged at 200 × g for 10 min at 4°C. The wash is repeated once and the cells are resuspended in HBSS with 5% PCS and added to the agar-medium mixture for assessment of surviving clonogenic cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Allen SL, et al. Amonafide: a potential role in treating acute myeloid leukemia. Expert Opin Investig Drugs. 2011 Jul;20(7):995-1003. [Content Brief]

[2]. Andersson BS, et al. In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res. 1987 Feb 15;47(4):1040-4. [Content Brief]

[3]. Ajani JA, et al. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun;6(2):79-85. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5295 mL	17.6473 mL	35.2945 mL	88.2363 mL
	5 mM	0.7059 mL	3.5295 mL	7.0589 mL	17.6473 mL
	10 mM	0.3529 mL	1.7647 mL	3.5295 mL	8.8236 mL
	15 mM	0.2353 mL	1.1765 mL	2.3530 mL	5.8824 mL
	20 mM	0.1765 mL	0.8824 mL	1.7647 mL	4.4118 mL
	25 mM	0.1412 mL	0.7059 mL	1.4118 mL	3.5295 mL
	30 mM	0.1176 mL	0.5882 mL	1.1765 mL	2.9412 mL
	40 mM	0.0882 mL	0.4412 mL	0.8824 mL	2.2059 mL
	50 mM	0.0706 mL	0.3529 mL	0.7059 mL	1.7647 mL
	60 mM	0.0588 mL	0.2941 mL	0.5882 mL	1.4706 mL
	80 mM	0.0441 mL	0.2206 mL	0.4412 mL	1.1030 mL
	100 mM	0.0353 mL	0.1765 mL	0.3529 mL	0.8824 mL

Keywords

Amonafide

5 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Amonafide

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 Amonafide

Topoisomerase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (5)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Amonafide

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 Amonafide

Topoisomerase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (5)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Amonafide 関連分類

HY-10982 関連分類